Akers Biosciences Receives Buy Rating from Daniel Stewart & Co (AKR)
Akers Biosciences (LON:AKR)‘s stock had its “buy” rating reiterated by equities researchers at Daniel Stewart & Co in a research report issued on Thursday. They currently have a GBX 752 ($12.87) price target on the stock. Daniel Stewart & Co’s target price would suggest a potential upside of 176.47% from the company’s current price.
Shares of Akers Biosciences (LON:AKR) traded down 4.67% on Thursday, hitting GBX 255.00. 7,112 shares of the company’s stock traded hands. Akers Biosciences has a 1-year low of GBX 156.00 and a 1-year high of GBX 325.00. The stock has a 50-day moving average of GBX 275.3 and a 200-day moving average of GBX 339.7.
Separately, analysts at Aegis initiated coverage on shares of Akers Biosciences in a research note on Monday, June 9th. They set a “buy” rating on the stock.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.